[Clinical experience of therapeutic use of cefmetazole (cefmetazon) or bronchopneumonia (author's transl)].
1. Therapeutic effects of cefmetazole (cefmetazon, CMZ) were examined in 22 cases of bronchopneumonia. 2. Among the 22 cases, 17 cases (77%) showed better response than 'effective'. However, 10 cases (91%) showed better response than 'effective' if a daily of 4 g (11 cases) was taken into consideration. 3. No particular symptomatic side effect of CMZ was shown. Abnormality in such laboratory tests as transaminase (1 case of GOT, and 2 cases of GPT) and 1 case of alkaline phosphatase were observed, and the abnormality was ascribable to CMZ administration.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001996:Bronchopneumonia / Q000188:drug therapy*; D015311:Cefmetazole; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D015311:Cefmetazole